Additionally, NEC-driving transcription factors such as N-MYC, ASCL1, and NeuroD1, which are known to promote lineage transition in the context of TP53 and RB1 loss [35, 38], were further included in our experimental design (Fig. 5A). The gene discussed is ASCL1; the disease is neuroendocrine carcinoma.